Board and Management

The members of Cypralis’ board and management team are highly experienced with proven track records in medicinal chemistry (with world-leading capabilities in PPIase chemistry), pharmacology, drug discovery & development; IP strategy; fundraising, business development & licensing; project & financial management; and delivering successful investor exits.


Hans Fliri Ph.D, Chairman/CEO

Hans Fliri has more than 35 years’ experience in the healthcare sector having held senior management positions in global pharmaceutical and biotechnology companies. He held research and management positions at Sandoz (now Novartis) in Basel between 1977 and 1994, was Senior Director of anti-infective drug discovery and lead generation at Rhone-Poulenc Rorer and later Aventis in Paris (1994-2000) and Vice President of Drug Discovery at Cetek Corporation (2001-2002) in the US. He is a founder of Selcia Holdings Ltd and led the company through a management buy-out from Scynexis Europe in 2005. He holds a PhD in chemistry from the University of Innsbruck and is the author of approximately 50 scientific articles and patents. He is an acknowledged expert in macrocyclic chemistry and a leader in the field of PPIase drug discovery.

Nicola Baker-Munton CPA EPA, Non-Executive Director

Nicola Baker-Munton is the founder and Chief Executive Officer of Stratagem Intellectual Property Management Limited and has over 28 years’ experience in the IP profession. Based on a joint honours degree in biology and biochemistry, Nicola qualified as a UK Patent Agent and European Patent Attorney at The Wellcome Foundation Limited and founded Stratagem IPM in 1999, which has subsequently become the leading specialist company providing active strategic management of intellectual property portfolios from inception through development to market.

Andreas Rummelt Ph.D, Non-Executive Director

Andreas Rummelt has over 25 years of experience in the pharmaceutical industry, primarily with Novartis focusing on drug development, technical operations, quality assurance and global manufacturing strategy. He was CEO of Sandoz (generics division of Novartis) from 2004 until 2008 and a Member of the Novartis Executive Committee from 2006 until 2010. He is Managing Partner of InterPharmaLink AG and is on the boards of Alexion Pharmaceuticals, Inc., Selcia Ltd, Xellia Pharmaceuticals ApS and Habasit Holding AG/Habasit AG.  Dr. Rummelt received Executive Training in General Management and Leadership from IMD, INSEAD and Harvard Business School.  He graduated with a Ph.D in Pharmaceutical Sciences from the University of Erlangen-Nürnberg, Germany in 1983.


Michael Peel Ph.D, CSO

Michael Peel has 30 years’ experience in the pharmaceutical industry and joined Cypralis from Scynexis Inc, where he was Director of Discovery.  Whilst at Scynexis he was responsible for building their chemistry services group and directing DMPK and biology for in-house research.  He also led their in-house cyclophilin inhibitor programs, opening several avenues into new biology and new potential applications for cyclophilin inhibition in virology, ophthalmology and immunology.  Prior to Scynexis, Mike worked for Glaxo Inc., based in Research Triangle Park, North Carolina where he led several research projects in inflammation, cancer and virology, and played a key role in GSK’s kinase research effort throughout.  Mike holds a Ph.D in chemistry from Sheffield University and undertook his post-doctoral studies at Wayne State University (Detroit).

Kim Haworth MSc FCCA, CFO

Kim Haworth has over 25 years of financial and management experience, and specialises in many areas including pharmaceutical, manufacturing and financial services. She was European Group Controller for GE Life and Pensions from 2004 to 2008 and was part of a team to sell the insurance divisions to Swiss Re and LV=. She transferred to LV= as Financial Controller of their Retirement Solutions Division and later was part of a team to sell LV Asset Management division to Threadneedle Asset Management. In 2012 she went on to join Friends Life Investments as Finance Director and as part of a team to build Friends Life inhouse Asset Manager.  In 2016 she formed her own consultancy and acts as finance director to a portfolio of SME’s.  She has a MSc in finance and is a qualified accountant with ACCA.

Scientific Advisors 

John Davis Ph.D, Scientific Advisor

John Davis is Chief Scientific Officer of the Alzheimer’s Research UK Oxford Drug Discovery Institute. He has over 20 years’ drug discovery experience from SmithKline Beecham, GlaxoSmithKline, Convergence Pharmaceuticals and Selcia. He was a research fellow at the Ludwig Institute for Cancer Research and Salk Institute for 6 years before joining SmithKline Beecham (later GlaxoSmithKline) in 1993. His roles at GSK included director of neurodegeneration research and director of biology for pain and epilepsy research; he was also instrumental in the formation and management of several large collaborations with universities. He was a co-founder of Convergence Pharmaceuticals where he served as Head of Biology from 2010-2013, and then joined Selcia as Director of Discovery. He originally trained as a biochemist, has a PhD from Cambridge University and over 100 peer reviewed publications and patents.

Professor Robert Sutton, Scientific Advisor 

Robert Sutton is Professor of Surgery, Institute of Translational Medicine, University of Liverpool, Director of NIHR Pancreas BRU, NIHR Senior Investigator & an acknowledged world expert in treatment of acute pancreatitis.  Professor Sutton is highly engaged with industry and the infrastructure at Liverpool provides access to the MHRA accredited Phase I clinical research unit at The Royal Liverpool University Hospital.​

Please contact us to explore opportunities for collaboration or investment.